LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, today announced that it will be presenting for the second consecutive year, at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, on Monday, January 9, 2017 at 4:30 p.m. PT (7:30 p.m. ET).
During the presentation, Kevin Hrusovsky, Executive Chairman and CEO, will provide the Company’s vision, growth trajectory, and plan for transforming the science of precision health. Hrusovsky will also announce strategic advancements with long-term partners, including BioMérieux, a worldwide leader in in-vitro diagnostics, offering microbiological testing solutions for medical and industrial applications.
Quanterix’ ultra-sensitive technology, Simoa, has been validated by more than 80 third-party publications, demonstrating its revolutionary early detection diagnostic capabilities across a wide spectrum of therapeutic areas, including oncology, neurology, cardiology, infectious disease and inflammation. The Company has also received significant recognition, including being named the “Late Stage Leader” by Buzz of BIO.
“The recognition we have received over the past year for the transformational capabilities of our Simoa technology to change precision health and measure the continuum from health to disease has been inspiring,” says Hrusovksy. “This success validates the profound impact of the work we’re doing and sets us up for another milestone year. We look forward to sharing the latest developments that are accelerating our vision at this year’s event.”
Hrusovsky will be available to participate in one-on-one meetings with investors who are registered to attend the conference and a live webcast of the presentation will be available on www.quanterix.com.
Quanterix is a company that’s digitizing biomarker analysis to advance the science of precision health. The company’s digital health solution, Simoa, is changing the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. In doing so, Quanterix enables much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for applications in a majority of therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts.